Key Points
- Insider sale: On Dec. 31 Patrick Burnett sold 1,697 shares at $29.20 for $49,552.40, trimming his stake to 96,610 shares (a 1.73% decrease) valued at about $2.82M.
- Recent selling trend: Burnett has sold repeatedly since early November — a total of 36,933 shares for roughly $956K across multiple transactions — indicating sustained insider selling activity.
- Stock context: ARQT trades near its 52‑week high ($31.77), has a market cap of $3.55B, and carries a consensus "Moderate Buy" with an average price target of $29.00 amid mixed analyst ratings.
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Get Free Report) insider Patrick Burnett sold 1,697 shares of the stock in a transaction that occurred on Wednesday, December 31st. The stock was sold at an average price of $29.20, for a total value of $49,552.40. Following the sale, the insider directly owned 96,610 shares in the company, valued at $2,821,012. This represents a 1.73% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
Patrick Burnett also recently made the following trade(s):
- On Monday, December 15th, Patrick Burnett sold 11,500 shares of Arcutis Biotherapeutics stock. The stock was sold at an average price of $28.94, for a total value of $332,810.00.
- On Thursday, November 6th, Patrick Burnett sold 17,250 shares of Arcutis Biotherapeutics stock. The shares were sold at an average price of $24.18, for a total value of $417,105.00.
- On Wednesday, November 5th, Patrick Burnett sold 3,864 shares of Arcutis Biotherapeutics stock. The stock was sold at an average price of $23.72, for a total value of $91,654.08.
- On Monday, November 3rd, Patrick Burnett sold 2,622 shares of Arcutis Biotherapeutics stock. The stock was sold at an average price of $24.72, for a total value of $64,815.84.
Arcutis Biotherapeutics Stock Down 0.1%
ARQT stock opened at $29.00 on Friday. Arcutis Biotherapeutics, Inc. has a 52 week low of $11.13 and a 52 week high of $31.77. The business has a 50-day simple moving average of $27.73 and a 200 day simple moving average of $20.38. The company has a quick ratio of 3.28, a current ratio of 3.50 and a debt-to-equity ratio of 0.68. The company has a market cap of $3.55 billion, a PE ratio of -80.56 and a beta of 1.71.
Arcutis Biotherapeutics (NASDAQ:ARQT - Get Free Report) last released its earnings results on Tuesday, October 28th. The company reported $0.06 EPS for the quarter, beating the consensus estimate of ($0.10) by $0.16. The firm had revenue of $99.22 million for the quarter, compared to analyst estimates of $86.69 million. Arcutis Biotherapeutics had a negative net margin of 13.94% and a negative return on equity of 29.69%. Sell-side analysts anticipate that Arcutis Biotherapeutics, Inc. will post -1.33 EPS for the current fiscal year.
Hedge Funds Weigh In On Arcutis Biotherapeutics
A number of institutional investors and hedge funds have recently bought and sold shares of the company. Ieq Capital LLC bought a new position in Arcutis Biotherapeutics in the first quarter valued at about $345,000. State of Wyoming grew its holdings in Arcutis Biotherapeutics by 228.5% during the 1st quarter. State of Wyoming now owns 13,232 shares of the company's stock worth $207,000 after acquiring an additional 9,204 shares during the last quarter. Graham Capital Management L.P. increased its position in Arcutis Biotherapeutics by 40.2% in the 1st quarter. Graham Capital Management L.P. now owns 37,617 shares of the company's stock valued at $588,000 after acquiring an additional 10,780 shares during the period. Advisors Asset Management Inc. increased its holdings in Arcutis Biotherapeutics by 26.2% in the first quarter. Advisors Asset Management Inc. now owns 28,187 shares of the company's stock valued at $441,000 after purchasing an additional 5,848 shares during the period. Finally, AQR Capital Management LLC raised its position in shares of Arcutis Biotherapeutics by 21.4% during the first quarter. AQR Capital Management LLC now owns 248,196 shares of the company's stock worth $3,882,000 after acquiring an additional 43,716 shares during the last quarter.
Analysts Set New Price Targets
Several brokerages have commented on ARQT. Wall Street Zen downgraded shares of Arcutis Biotherapeutics from a "strong-buy" rating to a "buy" rating in a research report on Saturday, December 27th. The Goldman Sachs Group boosted their price target on Arcutis Biotherapeutics from $19.00 to $29.00 and gave the stock a "neutral" rating in a report on Thursday, October 30th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Arcutis Biotherapeutics in a research note on Monday. HC Wainwright reiterated a "buy" rating and issued a $30.00 target price on shares of Arcutis Biotherapeutics in a research report on Wednesday, October 29th. Finally, Zacks Research cut shares of Arcutis Biotherapeutics from a "strong-buy" rating to a "hold" rating in a report on Monday, December 29th. Six analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $29.00.
View Our Latest Research Report on Arcutis Biotherapeutics
Arcutis Biotherapeutics Company Profile
(
Get Free Report)
Arcutis Biotherapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for immuno-inflammatory skin diseases. The company's research and development efforts center on targeted treatments that address the underlying biology of conditions such as plaque psoriasis, atopic dermatitis, seborrheic dermatitis and vitiligo. Arcutis employs a precision-medicine approach to deliver topical therapies designed to improve efficacy and tolerability compared with existing treatment options.
In August 2022, Arcutis received U.S.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
